Lipid Profile Alterations Across Coronary Heart Disease, Metabolic Syndrome, and Nephrotic Syndrome
Journal of Clinical Laboratory Analysis · 2026-04 · 40 (7)
DOI: 10.1002/jcla.70189 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 05.03.2026. Verfasst von Shudong Tan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China. Hauptthemen laut MEDLINE: Metabolic Syndrome, Nephrotic Syndrome, Coronary Disease, Lipids. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Joint Fund of Zhejiang Provincial Natural Science Foundation of China, Medical and Health Research Project of Zhejiang Province.
Abstract (Originalsprache)
Background
Dyslipidemia was a hallmark of metabolic disturbances in coronary heart disease (CHD), metabolic syndrome (MetS), and nephrotic syndrome (NS), yet the specific lipid profile patterns characteristic of each disease remained insufficiently defined.
Objective
This study aimed to clearly characterize and compare the qualitative features of lipid profiles across patients with CHD, MetS, and NS, and to identify key lipid markers associated with disease classification using multinomial logistic regression.
Methods
A total of 180 patients were enrolled and classified into three groups (CHD, MetS, NS) based on established diagnostic criteria. 60 healthy controls were concurrently enrolled. Lipidomic profiles and additional laboratory parameters were measured using validated analytical methods. Multinomial logistic regression was used to evaluate the associations between lipid parameters and disease categories.
Results
Lipid profile analysis revealed distinct qualitative trends across the disease groups. The CHD group demonstrated notably higher levels of TC and sdLDL, the MetS group exhibited prominent increases in TG and ApoE, while the NS group showed a broad and pronounced elevation across most measured lipid parameters. By contrast, the healthy control group consistently presented uniformly lower lipid levels. LASSO‐guided multinomial logistic regression identified TC, TG, ApoB, ApoE, and sdLDL‐C as independent predictors of disease classification.
Conclusions
Distinct patterns of dyslipidemia were observed in CHD, MetS, and NS. TC and sdLDL‐C might serve as robust markers for CHD, while ApoB demonstrated disease‐specific variability with diagnostic potential. These findings underscored the importance of detailed lipid profiling for improved risk stratification and targeted management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.
- Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Hangzhou, China.
- Department of Clinical Psychology, Hangzhou First People's Hospital, Hangzhou, China.
ORCID-Profile: Yaoyang Fu
Förderung
- Joint Fund of Zhejiang Provincial Natural Science Foundation of China
- Medical and Health Research Project of Zhejiang Province
Zitieren
APA
Tan, S., Qu, T., Ai, J., & Fu, Y. (2026). Lipid Profile Alterations Across Coronary Heart Disease, Metabolic Syndrome, and Nephrotic Syndrome. Journal of Clinical Laboratory Analysis, 40(7). https://doi.org/10.1002/jcla.70189
Vancouver
Tan S, Qu T, Ai J, Fu Y. Lipid Profile Alterations Across Coronary Heart Disease, Metabolic Syndrome, and Nephrotic Syndrome. Journal of Clinical Laboratory Analysis. 2026;40(7). doi:10.1002/jcla.70189
BibTeX
@article{Tan2026,
author = {Tan, Shudong and Qu, Tianji and Ai, Jing and Fu, Yaoyang},
title = {Lipid Profile Alterations Across Coronary Heart Disease, Metabolic Syndrome, and Nephrotic Syndrome},
journal = {Journal of Clinical Laboratory Analysis},
year = {2026},
volume = {40},
number = {7},
doi = {10.1002/jcla.70189}
}
EUVIMED